The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the European Academy of Dermatology and Venereology"
DOI: 10.1111/jdv.14251
Abstract: Hereditary angioedema (HAE) due to C1‐inhibitor deficiency (C1‐INH‐HAE) is a rare, potentially fatal, bradykinin‐mediated disease. Icatibant is a bradykinin B2 receptor antagonist originally approved in 2008 in the European Union and 2011 in the United… read more here.
Keywords: experience hereditary; hereditary angioedema; outcome survey; icatibant outcome ... See more keywords
Improvement in diagnostic delays over time in patients with hereditary angioedema: findings from the Icatibant Outcome Survey
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Translational Allergy"
DOI: 10.1186/s13601-018-0229-4
Abstract: The objective of this analysis was to evaluate the change over time in age at first symptoms, age at diagnosis, and delay in diagnosis using data from the Icatibant Outcome Survey (IOS). Patients with a… read more here.
Keywords: diagnosis; age; time; icatibant outcome ... See more keywords